The Latest Cardiac and Vascular News
KFAR-SABA, Israel–(BUSINESS WIRE)–CathWorks announced that the FAST-FFR pivotal trial has been added to the late-breaking clinical science program during the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego. FAST-FFR trial data will be presented in the Main Arena during the late-breaking science session that begins at 12 noon […]
KFAR-SABA, Israel–(BUSINESS WIRE)–CathWorks announced that it has submitted its CathWorks FFRangio™ System to the United States Food & Drug Administration (FDA) for review and 510(k) market clearance. The CathWorks FFRangio System is the non-invasive FFR platform that quickly and precisely delivers objective multi-vessel physiologic measurements to cost-effectively optimize and confirm intraprocedural PCI […]
KFAR-SABA, Israel–(BUSINESS WIRE)–CathWorks announced that its FAST-FFR trial is fully enrolled ahead of schedule. The trial is designed to evaluate efficacy of the CathWorks FFRangio™ System in terms of sensitivity and specificity when compared to conventional invasive Fractional Flow Reserve (FFR). Enrollment in the trial began on September 27, 2017 and […]
KFAR-SABA, Israel–(BUSINESS WIRE)–CathWorks announced the approval of a new CPT code 0523T for non-invasive, 3D FFRangio™ enabled interpretation of possible atherosclerotic stenosis during coronary angiography interventions. The code issuance is a major step forward in helping physicians objectively and cost-effectively determine if PCI (percutaneous coronary intervention) is indicated and revascularization […]
KFAR SABA, Israel, Oct. 27, 2017 /PRNewswire/ — CathWorks Ltd., a leader in the development of non-invasive Fractional Flow Reserve (FFR) measurements for guiding coronary interventions, announced today the appointment of James M. Corbett as its Chief Executive Officer. Corbett, an industry veteran with broad experience in global commercialization, has served as President, Boston Scientific International, […]
KFAR SABA, Israel, Oct. 24, 2017 /PRNewswire/ — Cathworks, a leader in the development of non-invasive Fractional Flow Reserve (FFR) measurements for guiding coronary interventions, announced today that the first patient has been enrolled in the FAST-FFR (FFRangio Accuracy vs. STandard FFR) clinical trial. This global pivotal trial is designed to assess the efficacy […]
KFAR SABA, Israel, Oct. 2nd, 2017 /PRNewswire/ — CathWorks Ltd., a leader in the development of non-invasive FFR measurements for guiding coronary interventions, today announced the completion of a $15.8M Series B round of financing, led by Quark Venture and Triventures. The syndicate also included Planven Investments, Pontifax, Corundum Open Innovation, and BioStar Venturesas well as a strategic investor. […]
